PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 176 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $828,000 | -89.4% | 14,000 | -78.5% | 0.24% | -85.2% |
Q3 2017 | $7,784,000 | -40.6% | 65,000 | -56.7% | 1.65% | -39.3% |
Q2 2017 | $13,110,000 | +56.6% | 150,000 | -33.3% | 2.72% | +74.7% |
Q1 2017 | $8,370,000 | +36.3% | 225,000 | +12.5% | 1.56% | +5.5% |
Q4 2016 | $6,140,000 | -39.0% | 200,000 | +33.3% | 1.48% | -9.4% |
Q3 2016 | $10,058,000 | +1952.7% | 150,000 | +2207.7% | 1.63% | +638.0% |
Q3 2015 | $490,000 | -76.0% | 6,500 | -62.9% | 0.22% | -66.6% |
Q2 2015 | $2,043,000 | -85.6% | 17,500 | -70.8% | 0.66% | -74.0% |
Q1 2015 | $14,166,000 | +149.5% | 60,000 | +100.0% | 2.55% | -6.5% |
Q4 2014 | $5,678,000 | +375.9% | 30,000 | +500.0% | 2.72% | +320.5% |
Q3 2014 | $1,193,000 | +1707.6% | 5,000 | +400.0% | 0.65% | +1278.7% |
Q2 2014 | $66,000 | -94.4% | 1,000 | -91.2% | 0.05% | -93.3% |
Q1 2014 | $1,180,000 | -54.4% | 11,330 | -54.7% | 0.70% | -56.0% |
Q4 2013 | $2,588,000 | – | 25,000 | – | 1.59% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
TOBAM | 318,384 | $23,994,000 | 0.94% |
Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |